Ziresovir
Ziresovir is an experimental antiviral drug currently under investigation for its potential use in the treatment of respiratory syncytial virus (RSV) infections. It is a small molecule inhibitor of the RSV fusion (F) protein, which is essential for the virus's ability to enter host cells and initiate an infection.
Mechanism of Action[edit | edit source]
Ziresovir works by inhibiting the fusion of the RSV virus with the host cell membrane, a critical step in the viral life cycle. The drug binds to the RSV F protein, preventing it from undergoing the conformational changes necessary for fusion with the host cell. This effectively blocks the virus from entering the cell and initiating an infection.
Clinical Trials[edit | edit source]
Ziresovir has undergone Phase I and II clinical trials to evaluate its safety, tolerability, and efficacy in treating RSV infections. The results of these trials have shown promise, with Ziresovir demonstrating a good safety profile and potential efficacy against RSV.
Potential Applications[edit | edit source]
If approved, Ziresovir could be used to treat RSV infections in high-risk populations, such as infants, the elderly, and immunocompromised individuals. It could also potentially be used prophylactically to prevent RSV infections in these high-risk groups.
See Also[edit | edit source]
References[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD